Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Precision Lysin Therapeutic (Acinetobacter baumannii program)
- Development stage
- Preclinical
- Lead developer
- Obulytix
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Obulytix's lead program is a Precision Lysin Therapeutic (PLT) targeting multidrug-resistant *Acinetobacter baumannii*, a pathogen frequently associated with hospital-acquired infections in critically ill patients. As an engineered protein biologic based on phage-derived lysins, it functions as an enzyme that rapidly and selectively cleaves bacterial cell walls, leading to potent bactericidal activity within seconds. The platform is designed to minimize antimicrobial resistance by specifically targeting the pathogen while leaving the healthy microbiota untouched. The therapy's mechanism is inspired by antibody-drug conjugates, focusing on rapid and selective destruction of bacterial cell walls. The program is currently in the preclinical stage of development and is designed for potential single-dose administration.
- Other names
- Precision Lysin Therapeutic (A. baumannii program)Obulytix A. baumannii programPrecision Lysin TherapeuticsPLTsObulytix engineered lysin
02
Targets
PGN (Peptidoglycan)
Beyond the preview
Go deeper on Precision Lysin Therapeutic (Acinetobacter baumannii program).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precision Lysin Therapeutic (Acinetobacter baumannii program).